What is Sub-Q Bionics?
Sub-Q Bionics is dedicated to developing an implantable lymphatic drainage system designed to alleviate lymphedema, a debilitating condition often experienced by cancer survivors. The company's proprietary technology aims to enhance lymphatic circulation through an implantable device that assists in fluid movement beneath the skin, thereby mitigating swelling, discomfort, and mobility issues. Headquartered in Stillwater, Minnesota, Sub-Q Bionics is positioned at the forefront of medical device innovation for chronic disease management.
How much funding has Sub-Q Bionics raised?
Sub-Q Bionics has raised a total of $1.5M across 1 funding round:
Angel/Pre-Seed
$1.5M
Angel/Pre-Seed (2026): $1.5M with participation from Mayo Clinic and Yeda Research and Development
Key Investors in Sub-Q Bionics
Mayo Clinic
Mayo Clinic is a globally recognized nonprofit healthcare organization renowned for its integrated clinical practice, education, and medical research. It specializes in comprehensive medical services and fosters medical advancement through extensive research and innovation.
Yeda Research and Development
Yeda Research and Development is the commercialization arm of the Weizmann Institute of Science, focusing on translating unique scientific discoveries into market-ready technologies across various sectors including MedTech and BioPlatforms.
What's next for Sub-Q Bionics?
The substantial enterprise-level funding indicates a pivotal growth phase for Sub-Q Bionics, likely enabling the company to advance its implantable lymphatic drainage system through further research, development, and clinical trials. This capital injection is expected to accelerate the path to market, potentially bringing a much-needed therapeutic solution to patients suffering from lymphedema. The company's focus on a significant unmet medical need suggests a strong potential for future expansion and strategic partnerships within the healthcare sector.
See full Sub-Q Bionics company page
